CL2018003443A1 - Tratamientos para el cancer. - Google Patents
Tratamientos para el cancer.Info
- Publication number
- CL2018003443A1 CL2018003443A1 CL2018003443A CL2018003443A CL2018003443A1 CL 2018003443 A1 CL2018003443 A1 CL 2018003443A1 CL 2018003443 A CL2018003443 A CL 2018003443A CL 2018003443 A CL2018003443 A CL 2018003443A CL 2018003443 A1 CL2018003443 A1 CL 2018003443A1
- Authority
- CL
- Chile
- Prior art keywords
- treatments
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609600.0A GB201609600D0 (en) | 2016-06-01 | 2016-06-01 | Cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003443A1 true CL2018003443A1 (es) | 2019-08-09 |
Family
ID=56410849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003443A CL2018003443A1 (es) | 2016-06-01 | 2018-11-30 | Tratamientos para el cancer. |
| CL2021002669A CL2021002669A1 (es) | 2016-06-01 | 2021-10-12 | (divisional de solicitud 3443-2018) tratamientos de cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002669A CL2021002669A1 (es) | 2016-06-01 | 2021-10-12 | (divisional de solicitud 3443-2018) tratamientos de cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11400107B2 (enExample) |
| EP (1) | EP3463384A1 (enExample) |
| JP (2) | JP7367910B2 (enExample) |
| KR (2) | KR20190011770A (enExample) |
| CN (1) | CN109562119A (enExample) |
| AU (1) | AU2017273124B2 (enExample) |
| BR (1) | BR112018074981A2 (enExample) |
| CA (1) | CA3025442C (enExample) |
| CL (2) | CL2018003443A1 (enExample) |
| EA (1) | EA038030B1 (enExample) |
| GB (1) | GB201609600D0 (enExample) |
| IL (1) | IL263123B (enExample) |
| MA (1) | MA45129A (enExample) |
| MX (1) | MX2018014840A (enExample) |
| MY (1) | MY199129A (enExample) |
| PH (1) | PH12018502491A1 (enExample) |
| SG (1) | SG11201810196RA (enExample) |
| WO (1) | WO2017207993A1 (enExample) |
| ZA (1) | ZA201807811B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3447061T3 (da) | 2011-03-01 | 2022-01-03 | NuCana plc | Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling |
| CN111909231B (zh) | 2014-11-28 | 2025-10-17 | 努卡那有限公司 | 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物 |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| AU2019360210B2 (en) * | 2018-10-17 | 2025-07-10 | Xibin Liao | 6-Mercaptopurine nucleoside analogues |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| JP7688152B2 (ja) | 2021-04-16 | 2025-06-03 | ギリアード サイエンシーズ， インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
| JP7719954B2 (ja) | 2021-08-18 | 2025-08-06 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物並びにその製造方法及び使用方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| WO2007056596A2 (en) | 2005-11-09 | 2007-05-18 | Wayne State University | Phosphoramidate derivatives of fau |
| CN104586832B (zh) | 2007-09-10 | 2018-02-16 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
| EP2274617A4 (en) | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| DK3447061T3 (da) | 2011-03-01 | 2022-01-03 | NuCana plc | Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling |
| AU2015265607A1 (en) | 2014-05-28 | 2016-11-17 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| KR102563040B1 (ko) * | 2014-06-25 | 2023-08-02 | 뉴카나 피엘씨 | 젬시타빈 전구 약물 |
| PT3119794T (pt) * | 2014-06-25 | 2018-01-15 | Nucana Biomed Ltd | Formulação que compreende um pró-fármaco de gemcitabina |
| CN111909231B (zh) * | 2014-11-28 | 2025-10-17 | 努卡那有限公司 | 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物 |
| KR20180021697A (ko) * | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
-
2016
- 2016-06-01 GB GBGB1609600.0A patent/GB201609600D0/en not_active Ceased
-
2017
- 2017-05-31 CN CN201780048221.8A patent/CN109562119A/zh active Pending
- 2017-05-31 JP JP2018563084A patent/JP7367910B2/ja active Active
- 2017-05-31 KR KR1020187037533A patent/KR20190011770A/ko not_active Ceased
- 2017-05-31 WO PCT/GB2017/051560 patent/WO2017207993A1/en not_active Ceased
- 2017-05-31 KR KR1020227034733A patent/KR20220142538A/ko not_active Ceased
- 2017-05-31 MY MYPI2018002142A patent/MY199129A/en unknown
- 2017-05-31 MA MA045129A patent/MA45129A/fr unknown
- 2017-05-31 EP EP17728604.4A patent/EP3463384A1/en active Pending
- 2017-05-31 IL IL263123A patent/IL263123B/en unknown
- 2017-05-31 EA EA201892803A patent/EA038030B1/ru unknown
- 2017-05-31 US US16/305,162 patent/US11400107B2/en active Active
- 2017-05-31 SG SG11201810196RA patent/SG11201810196RA/en unknown
- 2017-05-31 AU AU2017273124A patent/AU2017273124B2/en active Active
- 2017-05-31 CA CA3025442A patent/CA3025442C/en active Active
- 2017-05-31 BR BR112018074981-8A patent/BR112018074981A2/pt not_active Application Discontinuation
- 2017-05-31 MX MX2018014840A patent/MX2018014840A/es unknown
-
2018
- 2018-11-20 ZA ZA2018/07811A patent/ZA201807811B/en unknown
- 2018-11-26 PH PH12018502491A patent/PH12018502491A1/en unknown
- 2018-11-30 CL CL2018003443A patent/CL2018003443A1/es unknown
-
2021
- 2021-10-12 CL CL2021002669A patent/CL2021002669A1/es unknown
-
2022
- 2022-02-15 JP JP2022020897A patent/JP2022051965A/ja active Pending
- 2022-08-01 US US17/878,747 patent/US20230218655A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3025442C (en) | 2024-02-20 |
| MX2018014840A (es) | 2019-03-14 |
| MY199129A (en) | 2023-10-17 |
| MA45129A (fr) | 2021-05-05 |
| KR20220142538A (ko) | 2022-10-21 |
| SG11201810196RA (en) | 2018-12-28 |
| AU2017273124B2 (en) | 2022-09-29 |
| JP7367910B2 (ja) | 2023-10-24 |
| CL2021002669A1 (es) | 2022-05-27 |
| US20190374564A1 (en) | 2019-12-12 |
| GB201609600D0 (en) | 2016-07-13 |
| US11400107B2 (en) | 2022-08-02 |
| PH12018502491A1 (en) | 2019-09-09 |
| KR20190011770A (ko) | 2019-02-07 |
| JP2022051965A (ja) | 2022-04-01 |
| JP2019521971A (ja) | 2019-08-08 |
| AU2017273124A1 (en) | 2018-12-13 |
| EP3463384A1 (en) | 2019-04-10 |
| ZA201807811B (en) | 2024-05-30 |
| WO2017207993A1 (en) | 2017-12-07 |
| EA201892803A1 (ru) | 2019-06-28 |
| EA038030B1 (ru) | 2021-06-25 |
| IL263123B (en) | 2022-09-01 |
| US20230218655A1 (en) | 2023-07-13 |
| IL263123A (en) | 2018-12-31 |
| BR112018074981A2 (pt) | 2019-03-12 |
| CA3025442A1 (en) | 2017-12-07 |
| CN109562119A (zh) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261468A (en) | Uterine cancer treatments | |
| IL255217A0 (en) | Cancer neoepitopes | |
| PT3283527T (pt) | Terapêutica de combinação para o cancro | |
| PT3197456T (pt) | Tratamentos de cancro | |
| CL2014003041S1 (es) | Carcasa para aoutoinyector. | |
| IL263123A (en) | Cancer treatments | |
| PL3622953T3 (pl) | Leczenie skojarzone nowotworu | |
| EP3413927A4 (en) | CANCER THERAPY | |
| EP3593139C0 (en) | CANCER BIOMARKERS | |
| CL2015002084S1 (es) | Accesorio para calzado. | |
| DK3576740T3 (da) | Cancerbehandling | |
| EP3418613A4 (en) | ELECTRIC VALVE | |
| HUE040167T2 (hu) | Rákkezelés | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| BR112016029236A2 (pt) | métodos para tratar prurido. | |
| IT201600084952A1 (it) | Coglifrutta. | |
| LT3383385T (lt) | Melflufeno dozavimo režimas vėžio atveju | |
| PT3405212T (pt) | Vacinas para o cancro | |
| DK3407909T5 (da) | Cancerbehandling | |
| MA42609A (fr) | Polythérapie contre le cancer | |
| EP3576534A4 (en) | CANCER TREATMENT | |
| CL2017002884A1 (es) | Tratamientos para el cancer | |
| ES1158435Y (es) | Ascensor para espacios reducidos. | |
| PT3139932T (pt) | Regime de tratamento para composto de tiacumicina |